MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, KAPA had $3,219K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$3,219K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from the equity line of...
    • Proceeds from the sale and exerc...
    • Amortization of vendor advances
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable and accrued exp...
    • Prepaid expenses and other curre...

Cash Flow
2025-12-31
Proceeds from common stock issued for cash in connection with the closing of the initial public offering
0
Proceeds from notes payable - officers
0
Payment of deferred offering costs
0
Proceeds from the sale and exercise of prefunded warrants
3,058
Proceeds from the equity line of credit
3,602
Net cash provided by financing activities
6,660
Debt discount amortization
0
Fair value of common shares issued in connection with the conversion of accounts payable
0
Fair value of warrants issued in connection with convertible notes payable
0
Gain on settlement of accounts payable
0
Vendor advances
0
Amortization of vendor advances
2,170
Fair value of vested restricted stock units
482
Prepaid expenses and other current assets
13
Accounts payable and accrued expenses
-793
Net loss
-5,447
Amortization of intangible asset
160
Net cash used in operating activities
-3,441
Net increase in cash and cash equivalents
3,219
Net increase in cash and cash equivalents
3,219
Cash and cash equivalents, beginning of period
1,272
Cash and cash equivalents, end of period
4,491
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from the equityline of credit$3,602K Proceeds from the sale andexercise of prefunded...$3,058K Net cash provided byfinancing activities$6,660K Net increase in cashand cash...$3,219K Canceled cashflow$3,441K Amortization of vendoradvances$2,170K Fair value of vestedrestricted stock units$482K Amortization of intangibleasset$160K Net increase in cashand cash...$3,219K Net cash used inoperating activities-$3,441K Canceled cashflow$2,812K Net loss-$5,447K Accounts payable andaccrued expenses-$793K Prepaid expenses andother current assets$13K

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)